The conjugate vaccines market is expected to reach $13.5 billion by 2019 from $7.5 billion in 2014, at a CAGR of 12.5%. Major factors driving growth of this market include increasing use of conjugate vaccines for adults, rising number of regulatory approvals for conjugate vaccines, rising prevalence of diseases, and technological advancements. However, low accessibility to vaccines in remote areas and complex production procedure of conjugate vaccine are expected to restrain the growth of this market. Emerging economies such as India and China present an array of opportunities for this market.
North America dominates the conjugate vaccines market, with the U.S. accounting for a major market share. However, Asia is poised to grow at the highest CAGR during the forecast period owing to the governmental initiatives, rising focus of major players on the Indian market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.
Prominent players in the conjugate vaccines market are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India.
Scope of the Report
This research report covers the vaccines market by type, disease indication, pathogen type, end user, and geography.
Vaccines Market, by Type
Vaccines Market, by Disease Indication
Vaccines Market, by Pathogen Type
Vaccines Market, by Patient Stage
Vaccines Market, by Region
Benchmarking the rapid strategy shifts of the Top 100 companies in the Conjugate Vaccine MarketRequest For Special Pricing